Development of novel M 1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 15, 2012, Pages 5035-5040

  Melancon, Bruce J ^a,b   Utley, Thomas J ^a,b   Sevel, Christian ^a,b   Mattmann, Margrith E ^a,b   Cheung, Yiu Yin ^a,b   Bridges, Thomas M ^a,b   Morrison, Ryan D ^a,b   Sheffler, Douglas J ^a,b   Niswender, Colleen M ^a,b   Scott Daniels, J ^a,b   Jeffrey Conn, P ^a,b   Lindsley, Craig W ^a,b   Wood, Michael R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

M 1 antagonist; ML012; Muscarinic acetylcholine receptor 1; VU0452865; VU0455691

Indexed keywords

AZETIDINE DERIVATIVE; ML 012; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; UNCLASSIFIED DRUG; VU 0452865; VU 0455691; AZABICYCLO DERIVATIVE; AZETIDINE; CYTOCHROME P450; ISOPROTEIN; N (3 OXO 3 (4 (PYRIDIN 4 YL)PIPERAZIN 1 YL)PROPYL)BENZO(C)(1,2,5)THIADIAZOLE 4 SULFONAMIDE; N-(3-OXO-3-(4-(PYRIDIN-4-YL)PIPERAZIN-1-YL)PROPYL)BENZO(C)(1,2,5)THIADIAZOLE-4-SULFONAMIDE; SULFONAMIDE; THIADIAZOLE DERIVATIVE; VU0455691;

ANIMAL CELL; ARTICLE; BRAIN HOMOGENATE; CHEMICAL MODIFICATION; DRUG CLEARANCE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; MOLECULAR PROBE; PROTEIN BINDING; SYNTHESIS;

ANIMALS; AZABICYCLO COMPOUNDS; AZETIDINES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MOLECULAR PROBES; PROTEIN BINDING; PROTEIN ISOFORMS; RATS; RECEPTOR, MUSCARINIC M1; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIADIAZOLES;

EID: 84863984192     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.06.018     Document Type: Article

References (21)

1. T.I. Bonner, N.J. Buckley, A.C. Young, and M.R. Brann Science 237 1987 527
2. T.I. Bonner, A.C. Young, M.R. Brann, and N.J. Buckley Neuron 1 1988 403
3. J. Wess Annu. Rev. Pharmacol. Toxicol. 44 2004 423
4. C.J. Langmead, J. Watson, and C. Reavill Pharmacol. Ther. 117 2008 232
5. J. Wess Crit. Rev. Neurobiol. 10 1996 69
6. J. Wess, R.M. Eglen, and D. Gautam Nat. Rev. Drug Disc. 6 2007 721
7. T.M. Bridges, E.P. LeBois, C.R. Hopkins, M.R. Wood, J.K. Jones, P.J. Conn, and C.W. Lindsley Drug News Perspect. 23 2010 229
8. J.N. Heinrich, J.A. Butera, T. Carrick, A. Kramer, D. Kowal, T. Lock, K.L. Marquis, M.H. Pausch, M. Popiolek, S.-C. Sun, E. Tseng, A.J. Uveges, and S.C. Mayer Eur. J. Pharmacol. 605 2009 53
9. F.P. Bymaster, C.A. Whitesitt, H.E. Channon, N. DeLapp, J.S. Ward, D.O. Calligaro, L.A. Shipley, J.L. Buelke-Sam, N.C. Bodick, L. Farde, M.J. Sheardown, P.H. Olesen, K.T. Hansen, P.D. Suzdak, M.D.B. Swedberg, P. Sauerberg, and C.H. Mitch Drug Dev. Res. 40 1997 158
10. A. Shekhar, W.Z. Potter, J. Lightfoot, J. Lienemann, S. Dube, C. Mallinckrodt, F.P. Bymaster, D.L. McKinzie, and C.C. Felder Am. J. Psychiatry 165 2008 1033
11. M.L. Woolley, H.J. Carter, J.E. Gartlon, J.M. Watson, and L.A. Dawson Eur. J. Pharmacol. 603 2009 147
12. D.J. Sheffler, R. Williams, T.M. Bridges, L.M. Lewis, Z. Xiang, A.S. Kane, N.E. Byun, S. Jadhav, M.M. Mock, F. Zheng, L.M. Lewis, C.K. Jones, C.M. Niswender, C.D. Weaver, C.W. Lindsley, and P.J. Conn Mol. Pharmacol. 76 2009 356
13. T.M. Bridges, J.P. Kennedy, M.J. Noetzel, M.L. Breininger, P.R. Gentry, P.J. Conn, and C.W. Lindsley Bioorg. Med. Chem. Lett. 2010 1972 20
14. P.R. Reid, T.M. Bridges, D.J. Sheffler, H.P. Cho, L.M. Lewis, E. Days, J.S. Daniels, C.K. Jones, C.M. Niswender, C.D. Weaver, P.J. Conn, C.W. Lindsley, and M.R. Wood Bioorg. Med. Chem. Lett. 21 2011 2697
15. S.D. Kuduk, R.K. Chang, C.N. Di Marco, W.J. Ray, L. Ma, M. Wittmann, M.A. Seager, K.A. Koeplinger, C.D. Thompson, G.D. Hartman, and M.T. Bilodeau ACS Med. Chem. Lett. 1 2010 263
16. A.E. Brady, C.K. Jones, T.M. Bridges, J.P. Kennedy, A.D. Thompson, J.U. Heiman, M.L. Breininger, P.R. Gentry, H. Yin, S.B. Jadhav, J.K. Shirey, P.J. Conn, and C.W. Lindsley J. Pharmacol. Exp. Ther. 327 2008 941
17. T.M. Bridges, J.P. Kennedy, C.R. Hopkins, P.J. Conn, and C.W. Lindsley Bioorg. Med. Chem. Lett. 20 2010 5617
18. S. Veeraragavan, N. Bui, J.R. Perkins, L.A. Yuva-Paylor, R.L. Carpenter, and R. Paylor Psychopharmacology 217 2011 143
19. A. Healy, R. Rush, and T. Ocain ACS Chem. Neurol. 2 2011 402
20. B.J. Melancon, T.M. Bridges, A.P. Lamers, G.A. Sulikowski, D.J. Sheffler, C.M. Niswender, M.J. Noetzel, T.J. Utley, J.S. Daniels, R.D. Morrison, C.K. Jones, P.J. Conn, C.W. Lindsley, and M.R. Wood Bioorg. Med. Chem. Lett. 22 2012 1044
21. For information on the MLPCN and information on how to request probe compounds, such as ML012, see: http://mli.nih.gov/mli/mlpcn/.